These innovative molecules represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://lawsonhlgk808148.ltfblog.com/37709339/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide